The study is being conducted to evaluate the efficacy, and safety of HRS5580 for preventing of postoperative nausea and vomiting in adults. To explore the reasonable dosage of HRS5580 for postoperative nausea and vomiting.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
235
Beijing Friendship Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Third Xiangya Hospital of Central South University
Changsha, Hu'nan, China
No vomiting rate within 72 hours after extubation
Time frame: at 72 hours after extubation
Complete response rate (defined as the proportion of subjects without vomiting and receiving no rescue therapy) at 24, 48, 72, 96, and 120 hours after extubation
Time frame: at24, 48, 72, 96, and 120 hours after extubation
No vomiting at 24, 48, 96, and 120 hours after extubation,
Time frame: at 24, 48, 96, and 120 hours after extubation
Proportion of subjects who did not experience significant nausea within 24, 48, 72, 96, and 120 hours after extubation
Time frame: at 24, 48, 72, 96, and 120 hours after extubation
Proportion of participants not receiving rescue medication within 24, 48, 72, 96, and 120 hours of extubation
Time frame: at 24, 48, 72, 96, and 120 hours of extubation
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Ondansetron
blank preparation.